LeqvioActive Ingredient(s): Inclisiran
FDA Approved: * December 22, 2021
Pharm Company: * NOVARTIS PHARMS CORP
Category: Heart (Cardiac)
Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9. Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NIC... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Leqvio 284 mg/1.5ml Subcutaneous Injection, SolutionNDC: 0078-1000
Novartis Pharmaceuticals Corporation